Increased Potency of DsiRNA-EX Conjugates Seen at Low Doses in
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA
interference (RNAi) therapeutics, today announced that Douglas M.
Fambrough, Ph.D., president and chief executive officer, will present at
the Leerink Partners 4th Annual Rare Disease Roundtable. The
presentation will take place on Wednesday, September 30, 2015 at 10:40
a.m. ET at Le Parker Meridien Hotel in New York City.
The presentation will include new data showing advances in delivery
potency with DsiRNA-EX Conjugates. In mice, a single dose of ~0.6 mg/kg
mediated 50% reduction in gene expression. This is comparable to or
better than results for similarly delivered RNA molecules currently in
"We are very pleased with the performance of our latest DsiRNA-EX
Conjugates in preclinical studies," said Bob D. Brown, Ph.D., chief
scientific officer and senior vice president of research and development
at Dicerna. "Our continued rapid progress illustrates the power and
flexibility of Dicerna's proprietary DsiRNA platform. We are now
applying our advances in potency across multiple target genes to build a
pipeline of investigational liver-targeted therapies."
A live webcast of the presentation can be accessed by visiting "Events
& Presentations" in the Investors and Media section on the
Company's website at www.dicerna.com.
An archived replay of the webcast will be available on the Company's
website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative treatments for rare,
inherited diseases involving the liver and for cancers that are
genetically defined. The company is using its proprietary RNA
interference (RNAi) technology platform to build a broad pipeline in
these therapeutic areas. In both rare diseases and oncology, Dicerna is
pursuing targets that have been difficult to address using conventional
approaches, but where connections between targets and diseases are well
understood and documented. The company intends to discover, develop and
commercialize novel therapeutics either on its own or in collaboration
with pharmaceutical partners.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statements. DsiRNA-EX Conjugate-mediated delivery
technology is in preclinical development, and the process by which a
preclinical technology could potentially lead to an approved product is
long and subject to significant risks and uncertainties. Applicable
risks and uncertainties include those relating to our preclinical and
clinical research and other risks identified under the heading "Risk
Factors" included in our most recent Form 10-K filing and in other
future filings with the SEC. The forward-looking statements contained in
this press release reflect Dicerna's current views with respect to
future events, and Dicerna does not undertake and specifically disclaims
any obligation to update any forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150930005728/en/
Peter Vozzo, 443-213-0505
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media